The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension
High Blood Pressure

About this trial
This is an interventional treatment trial for High Blood Pressure focused on measuring Nitric Oxide, Adrenergic beta-Antagonists, Antihypertensive Agents, Vasodilator Agents, Anti-Arrhythmia Agents, Sympatholytics, Vascular Resistance, Neurotransmitter Agents, Cardiovascular Diseases, Metoprolol succinate, Therapeutic Uses, Metoprolol, Vascular Diseases, Nebivolol, Cardiovascular Agents, Endothelium-Dependent Relaxing Factors
Eligibility Criteria
Inclusion Criteria:
- Male or post-menopausal females aged 18-80 years.
- Subjects self-identified as black or African-American.
- Diagnosis of hypertension.
- Patients on current anti-hypertensive therapy that does not include beta blockade should have BP >135/85.
- Patients on anti-hypertensive therapy including beta blockers will have their beta blockers discontinued gradually over 2 weeks before enrolment.
- Concomitant therapy: Patients will be allowed to be on concomitant therapy with aspirin, statins, thiazide diuretics, calcium antagonists (for treatment of hypertension), clonidine, or vasodilators. Patients will be on stable medical therapy for at least 2 months before recruitment. Patients with previous treatment with beta adrenergic blockers (metoprolol, propranolol, atenolol, and labetalol) will also be eligible to participate, but will be randomized to the study beta blocker.
Exclusion Criteria:
- Initiation or change in dose of statin or other anti-hypertensive therapy within 2 months before the study
- Inability to return to Emory for follow-up testing
- Age < 21 or >80 years
- Premenopausal females with potential for pregnancy
- Acute infection in previous 2 weeks
- On angiotensin antagonists (ACE inhibitors or ARBs)
- History of substance abuse
- Current neoplasm
- Chronic renal failure [creatinine > 2.5 mg/dL] or liver failure (liver enzymes >2X normal)
- Acute coronary syndrome, Class IV heart failure, CVA, coronary intervention within 2 months
- Known aortic stenosis, hypertrophic cardiomyopathy.
- Inability to give informed consent
Sites / Locations
- Emory University
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Nebivolol followed by Metoprolol XL
Metoprolol XL followed by Nebivolol
Subjects are randomized to Nebivolol 5mg and titrate to Nebivolol 10mg two weeks after drug initiation. Ten weeks after titration subjects will cross over to Metoprolol XL 50mg and titrate to Metoprolol XL 100mg two weeks after cross over.
Subjects are randomized to Metoprolol XL 50mg and titrate to Metoprolol XL 100mg two weeks after drug initiation. Ten weeks after titration subjects will cross over to Nebivolol 5mg and titrate to Nebivolol 10mg two weeks after cross over.